Literature DB >> 27402056

Complement inhibition in C3 glomerulopathy.

Carla M Nester1, Richard J H Smith2.   

Abstract

C3 glomerulopathy (C3G) describes a spectrum of glomerular diseases defined by shared renal biopsy pathology: a predominance of C3 deposition on immunofluorescence with electron microscopy permitting disease sub-classification. Complement dysregulation underlies the observed pathology, a causal relationship that is supported by well described studies of genetic and acquired drivers of disease. In this article, we provide an overview of the features of C3G, including a discussion of disease definition and a review of the causal role of complement. We discuss molecular markers of disease and how biomarkers are informing our evolving understanding of underlying pathology. Research advances are laying the foundation for complement inhibition as a targeted approach to treatment of C3G.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C3 glomerulonephritis; C3 glomerulopathy; Complement; Dense deposit disease; Eculizumab; Membranoproliferative glomerulonephritis

Mesh:

Substances:

Year:  2016        PMID: 27402056     DOI: 10.1016/j.smim.2016.06.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  19 in total

Review 1.  CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Authors:  Peter F Zipfel; Thorsten Wiech; Emma D Stea; Christine Skerka
Journal:  J Am Soc Nephrol       Date:  2020-01-24       Impact factor: 10.121

Review 2.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

3.  Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.

Authors:  Johannes Holle; Lena Berenberg-Goßler; Kaiyin Wu; Ortraud Beringer; Florian Kropp; Dominik Müller; Julia Thumfart
Journal:  Pediatr Nephrol       Date:  2018-09-20       Impact factor: 3.714

Review 4.  Complementopathies and precision medicine.

Authors:  Eleni Gavriilaki; Robert A Brodsky
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  C3 glomerulopathy - understanding a rare complement-driven renal disease.

Authors:  Richard J H Smith; Gerald B Appel; Anna M Blom; H Terence Cook; Vivette D D'Agati; Fadi Fakhouri; Véronique Fremeaux-Bacchi; Mihály Józsi; David Kavanagh; John D Lambris; Marina Noris; Matthew C Pickering; Giuseppe Remuzzi; Santiago Rodriguez de Córdoba; Sanjeev Sethi; Johan Van der Vlag; Peter F Zipfel; Carla M Nester
Journal:  Nat Rev Nephrol       Date:  2019-03       Impact factor: 28.314

Review 6.  Protection of host cells by complement regulators.

Authors:  Christoph Q Schmidt; John D Lambris; Daniel Ricklin
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

7.  Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Daniel Ricklin; Richard J Smith; John D Lambris
Journal:  Trends Immunol       Date:  2017-04-14       Impact factor: 16.687

Review 8.  The renaissance of complement therapeutics.

Authors:  Daniel Ricklin; Dimitrios C Mastellos; Edimara S Reis; John D Lambris
Journal:  Nat Rev Nephrol       Date:  2017-12-04       Impact factor: 28.314

Review 9.  Glucocorticoids in the Treatment of Glomerular Diseases: Pitfalls and Pearls.

Authors:  Claudio Ponticelli; Francesco Locatelli
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-23       Impact factor: 8.237

10.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.